Shkreli investment gives KaloBios lifeline

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) gained $8.33 (402%) to $10.40 after it said Martin Shkreli and associated individuals acquired a majority stake in the company. KaloBios had said Nov. 13 that it would wind down operations and discontinue development of its programs.

According to an SEC filing, Shkreli acquired a total of 1.2 million shares for $1.6 million in a series of transactions on Monday and Tuesday. ...